Drug Ther Bull. 1999 Aug;37(8):59-61.
Clopidogrel (Plavix-Sanofi Winthrop/Bristol-Myers Squibb) and [symbol: see text] ticlopidine (Ticlid-Sanofi Winthrop) are inhibitors of platelet function and are promoted as potential alternatives to aspirin. Clopidogrel is licensed for the secondary prevention of vascular events in patients with established atherosclerotic disease. The manufacturer claims that clopidogrel is "significantly more effective at reducing myocardial infarction, stroke and vascular death" compared to aspirin. Ticlopidine is licensed as an alternative to aspirin for secondary prevention of stroke and coronary complications in patients with intermittent claudication. However, in the UK, ticlopidine is more commonly used with aspirin to prevent complications following insertion of coronary stents during angioplasty. We consider whether the claims for clopidogrel and the current use of ticlopidine are justified.
氯吡格雷（波立维 - 赛诺菲·温思罗普/百时美施贵宝）和噻氯匹定（抵克立得 - 赛诺菲·温思罗普）是血小板功能抑制剂，被宣传为阿司匹林的潜在替代品。氯吡格雷被批准用于已确诊动脉粥样硬化疾病患者血管事件的二级预防。制造商声称，与阿司匹林相比，氯吡格雷“在降低心肌梗死、中风和血管性死亡方面显著更有效”。噻氯匹定被批准作为阿司匹林的替代品，用于间歇性跛行患者中风和冠状动脉并发症的二级预防。然而，在英国，噻氯匹定更常用于与阿司匹林联合使用，以预防血管成形术期间冠状动脉支架置入后的并发症。我们探讨氯吡格雷的相关说法以及噻氯匹定目前的使用是否合理。
